6 Jun – The British Pharmaceutical GSK said Monday that its vaccine, Priorix, has been approved by the US Food and Drug Administration (FDA) for the prevention of measles, mumps, and rubella in people one year of age or older.
The vaccine can be given in two doses and can also be given as a second injection to people who have been previously vaccinated with a first dose of another MMR-containing vaccine, he said. GSK.
Childhood vaccination rates in the United States fell during the coronavirus pandemic. COVID-19, as many children skipped doctor’s appointments and states eased vaccination requirements during distance learning, according to a government study published last month.
“We are proud to make Priorix available in the United States for the first time, adding an option for providers to help protect patients against these highly contagious diseases,” said Chief Vaccine Officer GSK in the United States, Judy Stewart.
In recent years, measles outbreaks have occurred around the world, with more than 400,000 confirmed cases in 2019, reversing progress towards elimination of the disease in many countries.
Priorix, Priorix Tetra and the varicella vaccine Varilrix contributed about 260 million pounds ($325.99 million) to the turnover of vaccines GSK last year.
GSKwhich is spinning off its consumer health business, is turning its attention to vaccines and prescription drugs.
(1 US dollar = 0.7976 pounds)
—
